5 results about "Epstein bar virus" patented technology

The present disclosure relates to nucleic acid molecules (e.g., self-replicating RNAs (srRNAs) expressing one or more antigenic determinants derived from Epstein-Barr virus (EBV)), recombinant cells containing the nucleic acid molecules and pharmaceutical compositions, and uses of such srRNA molecules, recombinant cells and compositions for eliciting pharmacodynamic effects in a subject. Methods for preventing and / or treating a variety of health conditions associated with EBV infection are also provided.

Provided herein are engineered Epstein-Barr virus (EBV) polypeptides, polynucleotides encoding the same, related vectors and vaccine compositions, and related methods of making and using said compositions. The compositions disclosed herein may be useful for vaccination against EBV.

The present disclosure provides methods and compositions of modified oligonucleotide primer and probe combinations, structurally modified with locked nucleic acids, quenchers, and dyes, effective to detect tumor-derived Human Papilloma Virus (HPV) and tumor-derived Epstein-Barr virus (EBV) and, especially, to distinguish viral DNA derived from tumors from viral DNA derived from infectious viral particles.

The present invention relates to modified immune cells expressing T cell receptors (TCR) targeting Epstein-Barr virus (EBV) and their pharmaceutical uses. The present invention provides compositions comprising LMP2A specific TCR-T cell populations for the treatment of EBV-associated cancers and other indications, as well as methods for preparing and using the compositions. The present invention also provides nucleic acid sequences encoding the TCR and vectors thereof. The modified EBV-targeting immune cells of the present invention are activated upon binding tumor cells; they recognize targets and activate T-cell functions depending on presentation by major histocompatibility complex (MHC) molecules, while maintaining proliferation and antitumor activity. The EBV-targeting immune cells have demonstrated favorable antitumor efficacy in preclinical studies, offering a novel therapeutic strategy for patients with EBV-associated cancers.

Disclosed herein are methods for generating / expanding a population of immune cells comprising immune cells specific for Epstein-Barr virus (EBV) lytic antigens, the methods comprising stimulating immune cells specific for EBV lytic antigens by contacting peripheral blood mononuclear cells (PBMCs) with (i) one or more peptides corresponding to all or a portion of one or more EBV lytic antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or a portion of one or more EBV lytic antigens. Also disclosed are populations of immune cells comprising immune cells specific for EBV lytic antigens expanded according to these methods, and uses thereof.